In the first clinical trials, in the 1980s, of recombinant human IL-2 in primary immunodeficiency (Dopfer et al., 1984), AIDS (Kern et al., 1985), and cancer (Macdonald et al., 1990b), patients almost invariably developed eosinophilia, accompanied by high IL-5 titers. The gene discussed is IL2; the disease is cancer.